Repository logo
 
Publication

Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.

2016Journal article Restricted access
Simple item page
dc.contributor.authorLévi, FA
dc.contributor.authorBoige, V
dc.contributor.authorHebbar, M
dc.contributor.authorSmith, D
dc.contributor.authorLepère, C
dc.contributor.authorFocan, C
dc.contributor.authorKaraboué, A
dc.contributor.authorGuimbaud, R
dc.contributor.authorCarvalho, C
dc.contributor.authorTumolo, S
dc.contributor.authorInnominato, P
dc.contributor.authorAjavon, Y
dc.contributor.authorTruant, S
dc.contributor.authorCastaing, D
dc.contributor.authorDe Baere, T
dc.contributor.authorKunstlinger, F
dc.contributor.authorBouchahda, M
dc.contributor.authorAfshar, M
dc.contributor.authorRougier, P
dc.contributor.authorAdam, R
dc.contributor.authorDucreux, M
dc.contributor.authorAssociation Internationale pour Recherche sur Temps Biologique et Chronothérapie (ARTBC International)
dc.date.accessioned2017-06-26T10:12:29Z
dc.date.available2017-06-26T10:12:29Z
dc.date.issued2016
dc.description.abstractBACKGROUND: Systemic chemotherapy typically converts previously unresectable liver metastases (LM) from colorectal cancer to curative intent resection in ∼15% of patients. This European multicenter phase II trial tested whether hepatic artery infusion (HAI) with triplet chemotherapy and systemic cetuximab could increase this rate to 30% in previously treated patients. PATIENTS AND METHODS: Participants had unresectable LM from wt KRAS colorectal cancer. Main non-inclusion criteria were advanced extra hepatic disease, prior HAI and grade 3 neuropathy. Irinotecan (180 mg/m(2)), oxaliplatin (85 mg/m(2)) and 5-fluorouracil (2800 mg/m(2)) were delivered via an implanted HAI access port and combined with i.v. cetuximab (500 mg/m(2)) every 14 days. Multidisciplinary decisions to resect LM were taken after every three courses. The rate of macroscopic complete resections (R0 + R1) of LM, progression-free survival (PFS) and overall survival (OS) were computed according to intent to treat. RESULTS: The patient population consisted of 42 men and 22 women, aged 33-76 years, with a median of 10 LM involving a median of six segments. Up to 3 extrahepatic lesions of <1 cm were found in 41% of the patients. A median of six courses was delivered. The primary end point was met, with R0-R1 hepatectomy for 19 of the 64 previously treated patients, 29.7% (95% confidence interval 18.5-40.9). Grade 3-4 neutropenia (42.6%), abdominal pain (26.2%), fatigue (18%) and diarrhea (16.4%) were frequent. Objective response rate was 40.6% (28.6-52.3). Median PFS and OS reached 9.3 (7.8-10.9) and 25.5 months (18.8-32.1) respectively. Those with R0-R1 hepatectomy had a median OS of 35.2 months (32.6-37.8), with 37.4% (23.6-51.2) alive at 4 years. CONCLUSION: The coordination of liver-specific intensive chemotherapy and surgery had a high curative intent potential that deserves upfront randomized testing.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationAnn Oncol. 2016 Feb;27(2):267-74pt_PT
dc.identifier.doi10.1093/annonc/mdv548pt_PT
dc.identifier.issn1569-8041
dc.identifier.urihttp://hdl.handle.net/10400.10/1883
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherEuropean Society for Medical Oncologypt_PT
dc.subjectCetuximabpt_PT
dc.subjectClinical trialspt_PT
dc.subjectColorectal neoplasmspt_PT
dc.subjectAntineoplastic combined chemotherapy protocolspt_PT
dc.subjectLiver neoplasmspt_PT
dc.titleConversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceLondonpt_PT
oaire.citation.endPage274pt_PT
oaire.citation.startPage267pt_PT
oaire.citation.titleAnnals of Oncologypt_PT
oaire.citation.volume27pt_PT
rcaap.rightsclosedAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Annals of Oncology 2016, 27, 267 – 274.pdf
Size:
377.14 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ONC - Artigos publicados em revistas não indexadas